Loading…
Loading…
how you see the oncology portfolio evolving from here. With respect to novel combos
Just curious as to what your latest thinking is on business development. You've always referenced BD priorities that are geared towards the 2030s
Just one bigger picture question on the oncology franchise, maybe for Roopal. You've mentioned that you're watching the PD-1 VEGF class
if you could just maybe double click a little bit more on what the key levers are to bridge to that double-digit growth profile from where we sit today
can you just maybe double-click a little bit more on how you're going to be balancing capital allocation priorities?
do you have sufficient capacity today to manufacture for the U.S. market in the U.S.
Are you able to provide any quantitative framing on your views as it relates to the extent to which you think this erosion gets smoothed
can you just talk about what you're seeing in the contracting environment broadly speaking across the incretin portfolio
what are the learnings from this for the orforglipron ramp next year as it relates to the elasticity of demand across different price points
Where do you think this could stabilize? And how is that segment changing the landscape on pricing?
what is your expectation on market share dynamics in the next weeks and months from the CVS formulary loss?
any updated framing on what you're looking for would be helpful
speak to your level of confidence on the demand dynamics from that channel in the current environment